Theralase Technologies Inc. (TLTFF) Q4 2024 Earnings Call Transcript
…
0,121€
0,84%
Echtzeit-Aktienkurs Theralase Technologies Inc.
Bid:
Ask:
Nachrichten zur Theralase Technologies Inc. Aktie
Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript
…
Theralase continued to advance bladder cancer study during Q3
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) during the third quarter continued to make significant progress in its Study II clinical trial,…
Theralase Technologies completes private placement to support Phase 2 bladder cancer study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has completed a non-brokered private placement, raising approximately $666,400 through...…
Theralase Technologies’ bladder cancer treatment shows promising results in Phase 2 study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White joined Proactive to discuss the latest developments for the companys lead...…
Theralase Technologies CEO Roger DuMoulin-White Provides Update on Bladder Cancer Clinical Study
…
Theralase Technologies reports positive interim results from bladder cancer study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has provided an update on its ongoing bladder cancer clinical study involving Ruvidar, its...…
Theralase Technologies announces closure of financing
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has closed a non-brokered private placement, issuing 2.72 million units at $0.20 per unit, raising...…
Theralase Technologies announces extension of warrants
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF), a clinical-stage pharmaceutical company, announced its proposal to extend the expiry date of 10 million...…
Theraalse Technologies highlights Rudivar’s superior efficacy in preclinical HSV-1 research
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) reported that its lead drug formulation Rudivar has been shown to be more effective than…
Theralase Technologies highlights Rudivar’s superior efficacy in treating herpes simplex virus
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) reported that its lead drug formulation Rudivar has been shown to be more effective than…
Theralase Technologies’ Rutherrin shows promise against chemoresistance
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White talked with Proactive about the companys recent advancements in cancer...…
Theralase Technologies’ Rutherrin shows promise in tackling chemoresistance in lung cancer
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown to provide a “significant” enhancement...…
Theralase says Rutherrin shows promise in tackling chemoresistance in lung cancer
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown to provide a “significant” enhancement...…
Theralase Technologies’ Rutherrin shows promise in tacking chemoresistance in lung cancer
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown to provide a “significant” enhancement...…
Theralase Technologies CEO discusses innovative cancer therapy Rutherrin
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger DuMoulin-White joined Proactive to discuss the latest advancements in the company’s cancer...…
Theralase Technologies Inc. (TLTFF) Q2 2024 Earnings Call Transcript
…
Theralase Technologies reports ability to activate Rutherrin with diabetes drug
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown preclinically to be activated by the...…
Theralase nears completion of bladder cancer study with promising results
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) recently announced significant progress in the companys bladder cancer clinical study, now involving 72...…
Theralase Technologies bladder cancer study achieves key milestones
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF), a pioneer in the research and development of light and/or radiation-activated small molecules targeting...…
Theralase Technologies reports promising data in bladder cancer treatment
…
Theralase Technologies raises $0.8m in first tranche of placing
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) said it has raised C$775,000 from the first tranche of a non-brokered private placing. The company...…
Theralase Technologies reports Rutherrin boosts effectiveness of non-cancer drugs in cancer therapy
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin was able to repurpose non-cancer drugs for cancer...…
Theralese Technologies reports complete response in preclinical lung cancer model
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF). (TSXV OTCQB), a clinical-stage pharmaceutical company specializing in light and radiation-activated...…
Theralase Technologies reports lead drug Rutherrin enhances immunotherapy
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that new preclinical research has shown its lead drug formulation Rutherrin has demonstrated...…
Theralase reports preclinical research shows Rutherrin enhances chemotherapy efficacy
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that preclinical research results for its lead drug formulation, Rutherrin, has demonstrated...…
Theralase Technologies hails new combination treatment for NMI bladder cancer in pre-clinical tests
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) said that a combination of its lead compound with a widely used treatment to make a much more...…
Theralase Technologies Inc. (TLTFF) Q1 2024 Earnings Call Transcript
…
Theralase eyes Phase 1a trial for lung cancer therapy after preclinical success
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead compound Rudivar combined with transferrin to form the compound Rutherrin has...…
Theralase Technology unveils new research showing Rudivar’s effectiveness against multiple viruses
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that new research has shown that its lead asset Rudivar has proven effective in…
Theralase narrows Q1 loss as it advances bladder cancer trial
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) continued to advance its lead asset, bladder cancer treatment Rudivar, in the first quarter of…
Theralase brings on two Clinical Research Associates to advance bladder cancer trial
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has expanded its clinical team by hiring two Clinical Research Associates, Bhavya...…
Theralase granted Canadian patent for cancer vaccine technology
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced it has received a Canadian patent for its cancer vaccine. The newly issued patent…
Theralase Technologies Inc. (TLTFF) Q4 2023 Earnings Call Transcript
…
Theralase targets completion of Study II enrollment this year for bladder cancer treatment Rudivar
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is eyeing regulatory approval for its lead asset, the bladder cancer treatment Rudivar, by 2026,...…
Theralase to present data from Phase 2 bladder cancer study at Advisory Board meetings
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it will be hosting Advisory Board meetings at two upcoming urologic community forums to...…